Lululemon: The Situation Is Better Than You Think

An analyst identifies Lululemon (LULU) as deeply undervalued, trading at one-third its 5-year EV/EBITDA, despite competitive risks from 'dupes.' The bullish outlook is predicated on robust international sales growth and conservative financials, which are expected to provide resilience in diverse economic environments. The analysis projects a 37.3% internal rate of return (IRR) with limited downside, positioning LULU as a compelling contrarian buy; the analyst holds a long position in the stock.

Analysis

This analyst presents a strong bullish case for Lululemon (LULU), positioning it as a compelling contrarian buy opportunity. The core of the argument rests on a significant valuation discount, with the stock reportedly trading at one-third of its 5-year average EV/EBITDA multiple. This valuation is juxtaposed with robust fundamental performance, specifically strong international sales growth, which is identified as a key ongoing catalyst. The company's financials are described as conservative, providing a defensive cushion to navigate varied economic conditions. While the risk of competition from low-cost 'dupes' is acknowledged, the overall assessment remains highly optimistic, projecting a 37.3% internal rate of return (IRR) with limited downside based on a conservative model. The author's disclosed long position underscores a high-conviction stance on this deep value thesis.

Key Decisions for Investors

• Investors may consider the current valuation, at a third of its 5-year EV/EBITDA average, as a potential entry point for a contrarian, value-focused position.
• Closely monitor competitive pressures from 'dupes' in upcoming quarters, as this is the primary risk factor that could challenge the bullish thesis.
• Future performance should be gauged by the sustainability of international sales growth and margin resilience, which are the key drivers supporting the projected 37.3% IRR.
• Given the analyst's disclosed long position, the bullish sentiment is clear, but investors should align any potential investment with their own risk parameters and independent research.